(Sharecast News) - GSK announced on Thursday that its monoclonal antibody 'Nucala', or mepolizumab, delivered a statistically significant and clinically meaningful reduction in exacerbations for patients with chronic obstructive pulmonary disease (COPD), according to final results from the phase three MATINEE trial published in the New England Journal of Medicine.
The...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE